Back Back
Cell No. : Cell Name
RCB1897 : K562  update : 2022/12/20
CommentHuman cell line derived from chronic myelogenous leukemia. Differentiate into mature erythrocytes. TKG0210 (Deposited from Tohoku Univ.).
Comment from the depositor
Terms and conditionsThere is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC.
Order Form Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (
Basic information Depositor Obinata, Masuo
Originator Lozzio, C.B. & Lozzio, B.B.
Year of deposit 2004
Original cell TKG0210
Animal human < Mammals
Genus Homo
Species sapiens
Gender Female
Age at sampling 53 years
Tissue pleural effusion
Disease name chronic myelogenous leukemia
Classification cancer
History Cell Resource Center for Biomedical Research, Tohoku University(TKG0210)
Lifespan infinite
Morphology lymphoblast-like
Cellosaurus(Expasy) CVCL_0004
deposit info
lot info
Medium Medium List
Culture type Suspension cells
Medium and additives RPMI1640 + 10% FBS
Antibiotics Free
Passage method dilution
Culture information Passage ratio 1 : 8 split
SC frequency Subculture : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
Virus (HIV) LT 400
Isozyme LD, NP
Reference information Reference 5
User's Publication 10

To topTop
5042  Haruta Y, Seon BK.  Distinct human leukemia-associated cell surface glycoprotein GP160 defined by monoclonal antibody SN6.  Proc Natl Acad Sci U S A  1986  83(20):7898-902  PubMed ID: 3464004   DOI: 10.1073/pnas.83.20.7898
4603  Lozzio BB, Lozzio CB.  Properties and usefulness of the original K-562 human myelogenous leukemia cell line.  Leuk Res  1979  3(6):363-70  PubMed ID: 95026   DOI: 10.1016/0145-2126(79)90033-x
969  Rutherford TR, Clegg JB, Weatherall DJ.  K562 human leukaemic cells synthesise embryonic haemoglobin in response to haemin.  Nature  1979  280(5718):164-5  PubMed ID: 95354   DOI: 10.1038/280164a0
970  Andersson LC, Jokinen M, Gahmberg CG.  Induction of erythroid differentiation in the human leukaemia cell line K562.  Nature  1979  278(5702):364-5  PubMed ID: 570644   DOI: 10.1038/278364a0
4602  Lozzio CB, Lozzio BB.  Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome.  Blood  1975  45(3):321-34  PubMed ID: 163658  

To topTop
User's Publication
20321  Izumi K, Shindo T, Ngo HT, Nakayama-Hosoya K, Akahane K, Tamai M, Nguyen TTT, Kawana-Tachikawa A, Inukai T, Takaori-Kondo A.  KIR3DL1 Allotype-Dependent Modulation of NK Cell Immunity against Chronic Myeloid Leukemia.  Immunohorizons  2021  5(8):687-702  PubMed ID: 34433624   DOI: 10.4049/immunohorizons.2100054
11912  Chen Z, Nishimura N, Okamoto T, Wada K, Naora K.  Molecular Mechanism of Matrine from Sophora alopecuroides in the Reversing Effect of Multi-Anticancer Drug Resistance in K562/ADR Cells.  Biomed Res Int  2019    PubMed ID: 31871929   DOI: 10.1155/2019/1269532
12489  Anuchapreeda S, Rungrojsakul M, Tima S, Chiampanichayakul S, Krig SR.  Co-activation of WT1 and AP-1 proteins on WT1 gene promoter to induce WT1 gene expression in K562 cells  Cell Signal  2019  53:339-347  PubMed ID: 30395942   DOI: 10.1016/j.cellsig.2018.11.001
4269  Hirao T, Yamaguchi M, Kikuya M, Chibana H, Ito K, Aoki S.  Altered intracellular signaling by imatinib increases the anti-cancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia cells.  Cancer Sci.  2018    PubMed ID: 29121435   DOI: 10.1111/cas.13442
14533  Zhi Chen, Nobuhiro Nishimura, Takayuki Okamoto, Koichiro Wada, Kohji Naora  ABCB1-mediated multi-drug resistance in leukemic K562/ADR cells was reversed by Matrine, the main ingredient from Sophora alopecuroides  Proceedings for Annual Meeting of The Japanese Pharmacological Society  2018  WCP2018:PO3-7-14    DOI: 10.1254/jpssuppl.wcp2018.0_po3-7-14
13998  Nakai W, Yoshida T, Diez D, Miyatake Y, Nishibu T, Imawaka N, Naruse K, Sadamura Y, Hanayama R.  A novel affinity-based method for the isolation of highly purified extracellular vesicles  Sci Rep  2016  6:33935  PubMed ID: 27659060   DOI: 10.1038/srep33935
14001  Bologna-Molina R, Takeda Y, Kuga T, Chosa N, Kitagawa M, Takata T, Ishisaki A, Mikami T.  Expression of Wilms' tumor 1 (WT1) in ameloblastomas  J Oral Sci  2016  58(3):407-13  PubMed ID: 27665981   DOI: 10.2334/josnusd.15-0546
7421  Zhang B, Shimada Y, Kuroyanagi J, Ariyoshi M, Nomoto T, Shintou T, Umemoto N, Nishimura Y, Miyazaki T, Tanaka T.  In vivo selective imaging and inhibition of leukemia stem-like cells using the fluorescent carbocyanine derivative, DiOC5(3)  Biomaterials  2015  52:14-25  PubMed ID: 25818410   DOI: 10.1016/j.biomaterials.2015.02.009
13885  Umsumarng S, Pitchakarn P, Sastraruji K, Yodkeeree S, Ung AT, Pyne SG, Limtrakul P.  Reversal of human multi-drug resistance leukaemic cells by stemofoline derivatives via inhibition of P-glycoprotein function  Basic Clin Pharmacol Toxicol  2015  116(5):390-7  PubMed ID: 25265513   DOI: 10.1111/bcpt.12331
13882  Yamagishi N, Nakao R, Kondo R, Nishitsuji M, Saito Y, Kuga T, Hatayama T, Nakayama Y.  ncreased expression of sorcin is associated with multidrug resistance in leukemia cells via up-regulation of MDR1 expression through cAMP response element-binding protein  Biochem Biophys Res Commun  2014  448(4):430-6  PubMed ID: 24796664   DOI: 10.1016/j.bbrc.2014.04.125

Back Back Return Top Page